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Abstract
Background: Intravascular haemolysis has been associated with acute kidney injury (AKI) in different clinical settings
(cardiac surgery, sickle cell disease). Haemolysis occurs frequently in critically ill burn patients. The aim of this study was
to assess the predictive value of haptoglobin at admission to predict major adverse kidney events (MAKE) and AKI in
critically ill burn patients.
Methods: We conducted a retrospective, single-centre cohort study in a burn critical care unit in a tertiary centre,
including all consecutive severely burned patients (total burned body surface > 20% and/or shock and/or mechanical
ventilation at admission) from January 2012 to April 2017 with a plasmatic haptoglobin dosage at admission.
Results: A total of 130 patients were included in the analysis. Their mean age was 49 (34–62) years, their median total
body surface area burned was 29% (15–51%) and the intensive care unit (ICU) mortality was 25%. Early haemolysis was
defined as an undetectable plasmatic haptoglobin at admission. We used logistic regression to identify MAKE and AKI
risk factors. In multivariate analysis, undetectable haptoglobin was associated with MAKE and AKI (respectively, OR 6.33,
95% CI 2.34–16.45, p < 0.001; OR 8.32, 95% CI 2.86–26.40, p < 0.001).
Conclusions: Undetectable plasmatic haptoglobin at ICU admission is an independent risk factor for MAKE and AKI in
critically ill burn patients. This study provides a rationale for biomarker-guided therapy using haptoglobin in critically ill
burn patients.
Keywords: Haptoglobin, Intravascular haemolysis, Acute kidney injury, Burn patients, Major adverse kidney event
Background
Acute kidney injury (AKI) during an intensive care
unit (ICU) stay is associated with increased mortality
and morbidity [1, 2]. The pathophysiology of AKI in
critically ill patients remains poorly understood. Pre-
ventive or curative strategies for AKI are lacking and
urgently needed. In the specific population of critic-
ally ill burn patients, the prevalence of acute AKI has
been reported to be as high as 53%, with mortality
rates ranging from 35% to 70% [3–5]. Although
haemodynamic alterations, including hypovolaemic
shock and low cardiac output, may precipitate the
development of AKI [6], other factors are likely to
participate [7].
Among the factors contributing to AKI in critically
ill burn patients, intravascular haemolysis is a poten-
tial candidate. Severe burns have been associated with
haemolysis at the early stage of injury [8, 9]. Haem-
olysis has also been described as a strong causal fac-
tor for AKI in other situations such as sickle cell
disease [10, 11] or after cardiopulmonary bypass for
cardiovascular surgery [12, 13]. The pathophysiology
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of renal toxicity is complex and multifactorial, involv-
ing (1) cell-free haemoglobin (fHb), which is a scav-
enger of nitric oxide (NO), thereby decreasing its
bioavailability and inducing systemic vasoconstriction;
and (2) a direct toxicity of fHb that aggregates into
casts in the tubular lumen [14, 15]. Better and earlier
identification of haemolysis-related AKI may allow
the selection of patients who could benefit from spe-
cific and innovative treatments such as intravenous
haptoglobin administration [16]. The objective of this
study was to evaluate the association between plasma
haptoglobin level—a widely available biomarker of
intravascular haemolysis—and occurrence of major
adverse kidney events (MAKE) and AKI in critically
ill burn patients.
Methods
Study design and population
We conducted a single-centre cohort study in the burn
unit of St. Louis Hospital (Assistance Publique - Hôpi-
taux de Paris), Paris, France. The study was approved by
our local ethics committee (PRONOBURN study, comité
de protection des personnes IV, St-Louis Hospital; Insti-
tutional Review Board 00003835, protocol 2013/
17NICB). All medical records of the patients admitted to
our intensive care burn unit between January 2012 and
April 2017 were screened. All burn patients meeting the
following criteria were included in the study: total body
surface area (TBSA) burned > 20%, and/or mechanical
ventilation at admission, and/or catecholamine infusion
at admission, and a measurement of haptoglobin upon
admission.
Outcomes
The primary endpoint of the study was MAKE at day
90. The secondary endpoints were AKI and death within
90 days. MAKE was defined as a composite of the fol-
lowing criteria: death within 90 days, new renal replace-
ment therapy (RRT) during ICU stay, and/or no renal
recovery (defined as a ratio of serum creatinine at ICU
discharge to serum creatinine at admission > 125%) [17].
AKI was defined and staged according to the Kidney
Disease: Improving Global Outcomes criteria [17].
Serum creatinine (Screat) at hospital admission was used
to define the baseline Screat.
Measurements
We collected the following data: age, sex, body mass
index, TBSA, full-thickness body surface area burned,
mechanism of injury and patient characteristics, Simpli-
fied Acute Physiology Score II (SAPS II), Abbreviated
Burn Severity Index (ABSI) [18], Unit Burn Standard
[19], treatments administered during the first 7 days
after admission (hydroxocobalamin, aminoglycosides,
vasopressors), and 28- and 90-day mortality. Haptoglo-
bin measurement was performed using a haptoglobin
assay (Hitachi modular P analyser; Roche, Paris, France)
that is based on the principle of immunological agglutin-
ation. Anti-haptoglobin antibodies react with antigen in
the sample to form antigen-antibody complexes, which,
after agglutination, can be determined turbidimetrically.
The reference values of haptoglobin are from 0.3 g/L to
2 g/L; the detection limit is 0.1 g/L; and the linearity
limit is 5.2 g/L.
Patient management
Patients were resuscitated according to the St. Louis
Hospital Intensive Care Burn Unit resuscitation protocol
with the following haemodynamic targets: mean arterial
blood pressure > 65 mmHg, 0.5 ml/kg/h less than urine
output < 1 ml/kg/h, 2.5 L/minute/m2 less than cardiac
index < 3 L/minute/m2 and central venous oxygen satur-
ation > 70%. Norepinephrine was administered when re-
quired (diastolic arterial blood pressure < 50 mmHg and/
or systemic vascular resistance index < 1250 dyn/second/
cm−5/m2). Patients received initial fluid resuscitation
using an intravenous bolus of Ringer’s lactate 0.25 ml/
kg/%TBSA/h (which corresponds to the 2 ml/kg/%TBSA
in the first 8 h of the Parkland formula) with fluid infu-
sion adjusted to reach pre-defined haemodynamic tar-
gets. Cardiac function was systematically assessed on
admission by echocardiography. Cardiac index was mea-
sured by transpulmonary thermodilution using a
PiCCO2 monitor (Pulsion Medical Systems AG, Munich,
Germany). The PiCCO monitor was calibrated every 2 h
during the first 48 h.
Fig. 1 Flowchart
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Albumin 20% was administered to patients with
TBSA > 30% after the sixth hour after thermal injury to
reach a serum albumin concentration of 30–35 g/L.
When mechanical ventilation was initiated, tidal volume
was limited to 6–7 ml/kg to maintain an inspiratory
plateau pressure < 30 cmH2O and a transpulmonary
driving pressure < 15 cmH2O. Early enteral nutrition was
initiated within 24 h of admission. Glycaemic control
was adjusted to maintain glucose levels between 5 and
9 mmol/L. Surgical treatment included escharotomy or
fasciotomy as needed and early coverage of excised burn
wounds with autografts and/or allografts within the first
7 days after admission.
Statistical analysis
Continuous variables are reported as mean and SD or
median (25th–75th percentile range) as appropriate.
Categorical variables are expressed as count (percent).
Categorical variables were compared using the chi-
square test or Fisher’s exact test as appropriate. Continu-
ous variables were compared using Student’s t test or
the Mann- Whitney U test as appropriate.
Variables associated with MAKE and AKI in univari-
ate analysis were entered in a multivariable logistic re-
gression model with Lasso penalization [20] to identify
the factors independently associated with the out-
come. Inference was obtained using the post-selection
Table 1 Patient characteristics
All patients (n = 130) MAKE (n = 41) No MAKE (n = 89) p Value
Age, years 48.5 (34–61.8) 53 (47–67) 44 (29–58) 0.02
Sex, n (%)
Male 80 (61.5) 24 (58.5) 56 (62.9) 0.7
Female 50 (38.5) 17 (41.5) 33 (37.1)
BMI, kg/m2 25.1 (22.7–28.5) 26.2 (22.8–30.6) 24.9 (22.7–27.5) 0.06
Co-morbidities, n (%)
Hypertension 27 (20.8) 13 (31.7) 14 (15.7) 0.06
Diabetes mellitus 16 (12.3) 8 (19.5) 8 (9) 0.15
Chronic kidney disease 2 (1.5) 1 (2.4) 1 (1.1) 0.53
Vascular disease 8 (6.2) 3 (7.3) 5 (5.6) 0.71
Obesity 21 (16.1) 12 (29.3) 9 (10.1) 0.01
Smoking 14 (10.8) 2 (4.9) 12 (13.5) 0.22
Alcohol consumption 15 (11.5) 5 (12.2) 10 (11.2) 1
Psychiatric 17 (13.1) 6 (14.6) 11 (12.4) 0.78
Burn type, n (%)
Thermal 123 (94.6) 41 (100) 82 (92.1) 0.1
Electrical 7 (5.4) 0 (0) 7 (7.9)
Body surface area burned (%)
Total 28.5 (15–50.8) 50 (22.5–70) 20 (12–40) <0.0001
Full thickness 15 (4–32.2) 25 (15–56) 8 (1.8–25) <0.0001
ICU length of stay, days 27.5 (10–42.5) 18 (3–38) 29 (13.2–45) 0.42
Death in ICU, n (%) 33 (25.4) 33 (80.5) 0 (0) <0.0001
Day of death 15 (3–32) 15 (3–32) –
SAPS II 33 (19–49) 45 (35–72) 24 (15–39) <0.0001
UBS 67 (24–146) 110 (65–224) 46 (16–113) <0.0001
ABSI 8 (6–10) 11 (8–12) 7 (5–9) <0.0001
Serum creatinine on admission, μmol/L 67 (65–113) 88 (67–118) 64 (54–77) <0.0001
Maximal blood lactate concentration within 7 days, mmol/L 4.3 (2.8–7) 7 (5.2–9.4) 3.2 (2.2–4.7) <0.0001
Minimal serum haptoglobin level, g/L 0.6 (0.1–1.2) 0.1 (0.1–0.5) 0.8 (0.5–1.4) <0.0001
Undetectable haptoglobin level, n (%) 39 (30) 28 (68.3) 11 (12.4) <0.0001
Abbreviations: BMI Body Mass Index, ICU Intensive Care Unit, SAPS II Simplified Acute Physiology Score II, UBS Unit Burn Standard, ABSI Abbreviated Burn
Severity Index
Data are expressed as median ± 25th–75th interquartile range for continuous variables and count (percent) for discrete variables
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inference method for L1-penalized models described
by Taylor and Tibshirani [21]. Considering the rule of
thumb suggesting at least five to ten events for each
predictor variable included in the model [22], only the
most clinically relevant were included in the multivari-
ate model: creatinine at admission, SAPS II, ABSI, un-
detectable haptoglobin, need for catecholamine during
the first 7 days, and administration of hydroxocobala-
min. Model performance was estimated using the
cross-validated (tenfold) AUC. Mortality during the
first 90 days was described using the Kaplan-Meier es-
timate and modelled using a Cox proportional hazards
model. Survival curves were compared using the log-
rank test. In all comparisons, a p value < 0.05 was con-
sidered statistically significant. All analyses were per-
formed using R software version 3.3.3 for Mac (R
Foundation for Statistical Computing, Vienna,
Austria).
Results
Study population
Between January 2012 and April 2017, 1029 patients
were admitted (Fig. 1). Of these, 899 did not meet the
inclusion criteria. The characteristics of the 130 patients
included in the study are summarised in Table 1.
Outcomes
Forty-one patients developed MAKE, including 33
(80.5%) patients who died within 90 days. Twenty-six
patients required RRT, and 25 patients had no renal re-
covery. Seventy-three patients developed AKI during
the first 7 days, including 29 (39.7%) patients with stage
1 AKI, 17 (23.3%) with stage 2 and 27 (37%) with stage
3 AKI (Table 2). Only one patient developed AKI after
7 days. Among the 73 patients who developed AKI dur-
ing the first 7 days, 32 (44%) died during their ICU
stay.
Haptoglobin and outcomes
Undetectable plasma haptoglobin was observed in 39 pa-
tients (30%) at ICU admission. All but one had a total
burned surface area > 20%. Of these 39 patients, 34
(87.2%) developed AKI and 29 (74.4%) developed
MAKE. The minimal haptoglobin concentration was sig-
nificantly lower in patients with MAKE than in patients
without (p = 0.002) (Fig. 2). The frequency of MAKE by
haptoglobin quintile is illustrated in Fig. 3.
In univariate analysis, undetectable haptoglobin was
strongly associated with MAKE (OR 15.27, 95% CI
6.34–39.66, p < 0.001). In multivariate analysis, un-
detectable haptoglobin (OR 8.32, 95% CI 2.86–26.40,
p < 0.001), admission creatinine (OR 1.02, 95% CI
1.00–1.03, p = 0.05), need for catecholamine during
the first 7 days (OR 4.71, 95% CI 1.54–15.49, p = 0.01)
and SAPS II score (OR 1.04, 95% CI 1.01–1.07, p =
0.02) were independently associated with MAKE
(Table 3) (model discrimination AUC 0.88, 95% CI
0.80–0.96).
After adjustment, admission creatinine (OR 1.02,
95% CI 1.00–1.03, p = 0.05), SAPS II (OR 1.04, 95%
CI 1.01–1.07, p = 0.02), shock within 7 days (OR 4.71,
95% CI 1.54–15.49, p = 0.01) and undetectable
Table 2 Renal outcomes
All patients (n = 130) MAKE (n = 41) No MAKE (n = 89) p Value
Kidney aggression factors within 7 days, n (%)
Aminoglycoside 5 (3.9) 5 (12.2) 0 (0) 0.0026
Hydroxocobalamin 24 (18.5) 14 (34.1) 10 (11.2) 0.0031
Shock (use of catecholamine) 58 (44.6) 34 (82.9) 24 (27) <0.0001
AKI within 7 days, n (%) 73 (56.1) 39 (95.1) 34 (38.2) <0.0001
KDIGO stage of patients with AKI within 7 days 2 (1–3) 3 (2–3) 1 (1–2) <0.0001
Serum creatinine, μmol/L
Admission 67 (54–90) 88 (67–118) 64 (54–77) <0.0001
Maximum within 7 days 80 (65–113) 135 (85–206) 74 (64–86) <0.0001
ICU discharge (alive, without RRT) 49 (35–63) 64 (43–85) 49 (35–61) 0.07
Oliguria within 7 days, n (%) 63 (48.5) 35 (85.4) 28 (31.5) <0.0001
RRT n (%)
Within 7 days 18 (13.8) 18 (44) 0 (0) <0.0001
During ICU stay 26 (20) 26 (63.4) 0 (0) <0.001
Alive at ICU discharge 1 (0) 1 (2.4) –
Abbreviations: AKI Acute kidney injury, KDIGO Kidney Disease Improving Global Outcomes, ICU Intensive care unit, RRT Renal replacement therapy
Data are expressed as median ± 25th–75th interquartile range for continuous variables and number (percent) for discrete variables
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haptoglobin (OR 8.32, 95% CI 2.86–26.40, p < 0.001)
were independently associated with the occurrence of
AKI. In patients with undetectable haptoglobin, the
risk of death during the first 90 days was higher (23
[59%] of 39 versus 9 [10%] of 91; p < 0.0001) (Fig. 4).
This remained true after adjusting on severity (HR
5.11, 95% CI 2.21–11.78, p < 0.001).
Factors associated with undetectable haptoglobin
In multivariable analysis, TBSA was independently as-
sociated with undetectable haptoglobin (OR 1.04, 95%
CI 1.00–1.07, p = 0.03), whereas ABSI, smoke inhal-
ation and SAPS II were not (respectively, OR 1.16,
95% CI 0.89–1.5, p = 0.27; OR 1.88, 95% CI 0.72–4.95,
p = 0.20; and OR 1.01, 95% CI 0.98–1.03, p = 0.54).
Discussion
We observed 30% of undetectable plasma haptoglo-
bin in our cohort of critically ill burn patients. The
main finding of this study is that undetectable
haptoglobin on admission after burn injury is
strongly and independently associated with the oc-
currence of MAKE, AKI and 90-day mortality in
critically ill burn patients.
The association between haemolysis and AKI after
major aortic surgery [12] and in sickle cell disease
[11] has already been described. This is the first
Fig. 2 Box plot displaying minimal haptoglobin level between major adverse kidney events (MAKE) and no MAKE
Fig. 3 Major adverse kidney event (MAKE) count by haptoglobin quintiles
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study, to our knowledge, describing the association
between haptoglobin level and MAKE or AKI in a
population of critically ill burn patients. In 1943,
Shen et al. [8] described a 25% incidence of haemoly-
sis in 40 patients with combined second-degree and
third-degree thermal burns over 15–65% of the body
area. Eleven patients developed haemolysis as evi-
denced by the presence of haemoglobinuria. In the
literature on thermal burns, haemolysis is infrequently
reported as a complication of severe third-degree
burns [8]. In the present study, 38 (>97%) of 39 cases
with undetectable haemolysis had > 20% TBSA. TBSA
was strongly associated with undetectable haptoglobin,
even after adjustment for confounding factors. Physio-
pathology of renal toxicity of haemolysis is probably
multifactorial, including (1) the role of the fHb azote
monoxide (NO) scavenger, decreasing its bioavailability
and therefore inducing systemic vasoconstriction; and (2)
direct toxicity of fHb aggregating into casts in the tubular
lumen [14, 15].
We describe a high incidence of AKI in the first
week (56%), which is close to the incidence reported
by Palmieri et al., who described an incidence of 53%
in a retrospective cohort of 60 severely burned pa-
tients (>20% TBSA) [3]. In their study, they did not
describe the prevalence of MAKE; however, AKI was
strongly associated with mortality because 34% of
patients with AKI died, whereas no deaths were re-
ported among patients without AKI. In the present
study, we chose to use MAKE as the primary end-
point [17]. Of note, MAKE were driven largely by
RRT and mortality in our cohort. Moreover, the
prognosis of patients needing RRT was very poor,
with a 90-day mortality of 78%, which is again in
accord with the available literature. Yoon et al.
recently reported 84% mortality in burn patients
receiving RRT [23].
Recently, in a single-centre, retrospective, observa-
tional Japanese study, intra-operative administration
of haptoglobin was independently associated with a
lower risk of AKI after cardiovascular surgery [16],
suggesting a protective role of haptoglobin in bind-
ing fHB and therefore preventing its potential tox-
icity on the kidney. As far as we know, the use of
haptoglobin in burn patients has been described
only in a case report [24] of a 24-year-old man with
Fig. 4 Kaplan-Meier curve between patients with detectable and undetectable haptoglobin in the 72 first h
Table 3 Multivariable Lasso penalized logistic model: variables
associated with major adverse kidney events
Variable OR 95% CI p Value
Admission creatinine 1.02/μmol/L 1.00–1.03 0.03
SAPS II 1.03/1 point 1.00–1.06 0.05
ABSI 1.14/1 point 0.88–1.35 0.19
Shock in the first 7 days 4.18 1.44–10.59 0.02
Haptoglobin undetectable 6.33 2.34–16.45 <0.001
SAPS II Simplified Acute Physiology Score II, ABSI Abbreviated Burn
Severity Index
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100% TBSA and in a series of five patients [25]. In
the case report, haptoglobin was administered three
times over the first 24 h after the detection of
haemoglobinuria. Despite the severity of the initial
burn, the patient did not develop AKI in the five
5 days, suggesting a protective effect of intravenous
haptoglobin administration [24].
Our study has some limitations. First, this was an
observational study, and thus it describes an associ-
ation between haemolysis, MAKE and AKI, but not
necessarily a causal relationship. Second, it was a
single-centre study. This may limit the generalisabil-
ity of the results. However, our results rely on a
strong pathophysiological background and may open
a window for establishing methods to prevent
MAKE and AKI in this population. Third, low
haptoglobin level could arise from conditions other
than haemolysis. However, the differential diagnoses
appear to be very unlikely in our population. Hapto-
globin was measured upon admission, before hepatic
dysfunction occurs in critically ill patients. Finally,
even though burn patients are frequently transfused
after surgery for excision, none were transfused in
the early phase (first 96 h), and none had associated
trauma or haemorrhage.
Conclusions
This study shows that undetectable haptoglobin was
strongly associated with the development of MAKE, AKI
and 90-day mortality in a large cohort of patients with
severe burns. Further multicentre studies should be per-
formed to confirm these results. Interventional studies
using recombinant haptoglobin should be considered in the
future to improve outcome in patients with severe burns.
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